Hannah E Atlas, Bakary Conteh, Md Taufiqul Islam, Khuzwayo C Jere, Richard Omore, Doh Sanogo, Francesca Schiaffino, Mohammad Tahir Yousafzai, Naveed Ahmed, Alex O Awuor, Henry Badji, Jennifer Cornick, Erika Feutz, Sean R Galagan, Fadima C Haidara, Bri'Anna Horne, Md Ismail Hossen, Aneeta Hotwani, Eric R Houpt, Abdoulie F Jallow, Mehrab Karim, Adama Mamby Keita, Youssouf Keita, Farhana Khanam, Jie Liu, Thandizo Malemia, Alhagie Manneh, Christine J McGrath, Dilruba Nasrin, Maureen Ndalama, John Benjamin Ochieng, Billy Ogwel, Maribel Paredes Olortegui, Loyda Fiorella Zegarra Paredes, Tackeshy Pinedo Vasquez, James A Platts-Mills, Syed Qudrat-E-Khuda, Sonia Qureshi, Md Nazmul Hasan Rajib, Elizabeth T Rogawski McQuade, Shazia Sultana, Sharon M Tennant, Kirkby D Tickell, Desiree Witte, Pablo Peñataro Yori, Nigel A Cunliffe, M Jahangir Hossain, Margaret N Kosek, Karen L Kotloff, Firdausi Qadri, Farah Naz Qamar, Milagritos D Tapia, Patricia B Pavlinac
BACKGROUND: Shigella is a leading cause of acute watery diarrhea, dysentery, and diarrhea-attributed linear growth faltering, a precursor to stunting and lifelong morbidity. Several promising Shigella vaccines are in development and field efficacy trials will require a consortium of potential vaccine trial sites with up-to-date Shigella diarrhea incidence data. METHODS: The Enterics for Global Health (EFGH) Shigella surveillance study will employ facility-based enrollment of diarrhea cases aged 6-35 months with 3 months of follow-up to establish incidence rates and document clinical, anthropometric, and financial consequences of Shigella diarrhea at 7 country sites (Mali, Kenya, The Gambia, Malawi, Bangladesh, Pakistan, and Peru)...
March 2024: Open Forum Infectious Diseases